Popular Articles

National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support
The American Society of Interventional Pain Physicians (ASIPP) announced that the National All Schedules Prescription Electronic Reporting (NASPER) Act has received the support of Senator John D. Rockefeller IV of West Virginia and Senator Bob Corker of Tennessee.

Penn Medicine Honored For Its Historic Role In The History Of Microbiology
The University of Pennsylvania was honored by The American Society for Microbiology last Friday with a plaque dedication ceremony celebrating the designation of its third Milestones in Microbiology site. Formerly known as the Laboratory of Hygiene, the current Vagelos Laboratories resides on the University of Pennsylvania campus. Honorary speakers included Arthur H. Rubenstein, MBBCh, Dean, University of Pennsylvania School of Medicine; Alison O"Brien, PhD, President, American Society for Microbiology; and William B. Whitman, PhD, Trustee and Director of the Editorial Offices, Bergey"s Manual Trust.
News of the day
Exelixis Reports Encouraging Phase 1 Data To Be Presented At ASCO For XL228, A Multi-Targeted Inhibitor Of Key Cancer Signaling Kinases
Exelixis, Inc. (Nasdaq: EXEL) today reported encouraging data from an ongoing Phase 1 dose-escalation trial of XL228 in patients with advanced malignancies. XL228 is a small molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R), SRC, Aurora kinases, and fibroblast growth factor receptor types 1, 2, and 3 (FGFR1-3), which are associated with cancer cell proliferation, survival, and metastasis. The compound also inhibits BCR-ABL, including the T315I mutant form which is resistant to currently approved inhibitors. David Smith, MD, Professor of Medicine at the University of Michigan, an investigator on the Phase 1 trial, will present the data in an oral session (Abstract #3512) beginning at 4:15 p.m. local time on Saturday, May 30, 2009, at the American Society of Clinical Oncology Annual Meeting, which is being held May 29-June 2 in Orlando.
Sexual Health

How Superbugs Control Their Lethal Weapons

It appears that some superbugs have evolved to develop the ability to manipulate the immune system to everyone"s advantage. A team of researchers at The University of Western Ontario, led by Joaquin (Quim) Madrenas of the Robarts Research Institute, has discovered some processes that reduce the lethal effects of toxins from superbugs, allowing humans and microbes to co-evolve. This discovery may lead to novel alternatives to antibiotics that specifically target the toxic effects of these superbugs. The findings are being published in the journal Nature Medicine and are available online today. Madrenas holds a Canada Research Chair in Immunobiology and is a Professor of Microbiology & Immunology, and Medicine at the Schulich School of Medicine & Dentistry at Western. He also is head of Immunology at Robarts Research Institute and Director of the FOCIS Centre for Clinical Immunology and Immunotherapeutics. Staphylococcus (staph) aureus is the leading cause of infections in hospitals and the second most common cause of infections in the general population. By itself, it is linked to more than half a million hospital admissions a year in North America with estimated costs of more than $6 billion per year. Among the many weapons produced by this superbug, the most potent and lethal ones are known as superantigens. These lethal weapons cause massive and harmful activation of the immune system that leads to Toxic Shock Syndrome (TSS). TSS is a very serious disease that carries a high mortality, for which we do not have a specific treatment. Scientists have been puzzled as to why, when the body is directly exposed to the TSS toxins, a human can die within hours whereas individuals may carry toxin-producing staph and not get sick or die. What has the staph bug got that prevents the immune system of the host from being kicked into high gear? Madrenas and his collaborators at Western, Calgary and Chicago have identified the process that allows the bug to stay in the body without causing that massive activation of the immune system. The secret lies in molecules found in the cell wall of staph. These molecules bind to receptors known as TLR2 on immune cells of the host triggering the production of a protein called IL-10, an anti-inflammatory molecule that will prevent TSS. "It is clear that staph superbugs have developed strategies to control the toxicity of its lethal superantigen toxins, thereby preventing TSS. We believe that this is an important mechanism that warrants continued investigation. It also illustrates that evolution may operate not only by competition but also by networking ultimately leading to peaceful co-existence" says Madrenas. Based on these studies, Madrenas and colleagues have developed a computer model that will help predict the outcomes of encounters between staph and a host, and will reveal new aspects of these encounters. The multidisciplinary team led by Madrenas includes David Heinrichs, Ewa Cairns, Mansour Haeryfar, and John McCormick of the Departments of Microbiology and Immunology, and Medicine at The University of Western Ontario, as well as Paul Kubes from the University of Calgary and Gary An from Northwestern University in Chicago. The research was funded by the Canadian Institutes of Health Research and the Kidney Foundation of Canada. Kathy Wallis University of Western Ontario


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):